Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study

References

• Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24(18):2835–2840. doi:10.1097/QAD.0b013e328340a20921045636
   PubMed Web of Science ®Google Scholar
• Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115–125. doi:10.2147/ppa.s1033020517472
   PubMed Web of Science ®Google Scholar
• Cotte L, Ferry T, Pugliese P, et al. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large French multicenter cohort study. PLoS One. 2017;12(2):e0170661. doi:10.1371/journal.pone.017066128152047
   PubMed Web of Science ®Google Scholar
• Blanco JL, Montaner JS, Marconi VC, et al. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy. AIDS. 2014;28(17):2531–2539. doi:10.1097/QAD.000000000000042425574957
   PubMed Web of Science ®Google Scholar
• Scarsi KK, Havens JP, Podany AT, Avedissian SN, Fletcher CV. HIV-1 Integrase Inhibitors: a Comparative Review of Efficacy and Safety. Drugs. 2020;80(16):1649–1676. doi:10.1007/s40265-020-01379-932860583
   PubMed Web of Science ®Google Scholar
• Brooks KM, Sherman EM, Egelund EF, et al. Integrase Inhibitors: after 10 Years of Experience, Is the Best Yet to Come? Pharmacotherapy. 2019;39(5):576–598. doi:10.1002/phar.224630860610
   PubMed Web of Science ®Google Scholar
• Yang LL, Li Q, Zhou LB, Chen SQ. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors. Int J Antimicrob Agents. 2019;54(5):547–555. doi:10.1016/j.ijantimicag.2019.08.00831398480
   PubMed Web of Science ®Google Scholar
• Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254–258. doi:10.1128/AAC.00842-0919884365
   PubMed Web of Science ®Google Scholar
• Spagnuolo V, Castagna A, Lazzarin A. Bictegravir. Curr Opin HIV AIDS. 2018;13(4):326–333. doi:10.1097/COH.000000000000046829746268
   PubMed Web of Science ®Google Scholar
• Gilead S. Biktarvy 50 mg/200 mg/25 mg film-coated tablets: EU summary of product characteristics; 2018. Available from: http://www.ema.europa.eu/. Accessed 30 May, 2021.
   Google Scholar
• Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073–2082. doi:10.1016/S0140-6736(17)32340-128867499
   PubMed Web of Science ®Google Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, Abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–2072. doi:10.1016/S0140-6736(17)32299-728867497
   PubMed Web of Science ®Google Scholar
• Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379–396. doi:10.1001/jama.2018.843130043070
   PubMed Web of Science ®Google Scholar
• Ruzicka DJ, Kuroishi N, Oshima N, Sakuma R, Naito T. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database. BMC Infect Dis. 2019;19(1):505. doi:10.1186/s12879-019-4129-631182050
   PubMed Web of Science ®Google Scholar
• Moniz P, Alçada F, Peres S, et al. Durability of first antiretroviral treatment in HIV chronically infected patients: why change and what are the outcomes? J Int AIDS Soc. 2014;17(4 Suppl 3):19797. doi:10.7448/IAS.17.4.1979725397541
   PubMed Web of Science ®Google Scholar
• Birlie B, Braekers R, Awoke T, Kasim A, Shkedy Z. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia. BMC Infect Dis. 2017;17(1):453. doi:10.1186/s12879-017-2533-328655306
   PubMed Web of Science ®Google Scholar
• Abgrall S, Ingle SM, May MT, et al. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. AIDS. 2013;27(5):803–813.23719350
   PubMed Web of Science ®Google Scholar
• Ward D, Ramgopal M, Riedel DJ, et al. Real-World Experience with Dolutegravir-Based Two-Drug Regimens. AIDS Res Treat. 2020;2020:5923256. doi:10.1155/2020/592325632724674
   PubMed Web of Science ®Google Scholar
• Hayes E, Derrick C, Smalls D, Smith H, Kremer N, Weissman S. Short-term Adverse Events With BIC/FTC/TAF: postmarketing Study. Open Forum Infect Dis. 2020;7(9):ofaa285. doi:10.1093/ofid/ofaa28532908943
   PubMed Web of Science ®Google Scholar
• Welfare. HPAMoHa. Check your body weight everyday. Health Promotion Administration, Ministry of Health and Welfare, Taiwan. Available from: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=542&pid=9734. Accessed 30 May, 2021.
   Google Scholar
• Raffi F, Hanf M, Ferry T, et al. Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen. J Antimicrob Chemother. 2017;72(12):3425–3434. doi:10.1093/jac/dkx30028961719
   PubMed Web of Science ®Google Scholar
• Stephan C, Hill A, Sawyer W, van Delft Y, Moecklinghoff C. Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*. HIV Med. 2013;14(5):284–292. doi:10.1111/hiv.1200423171153
   PubMed Web of Science ®Google Scholar
• Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–774. doi:10.1097/00002030-200203290-0001211964533
   PubMed Web of Science ®Google Scholar
• Gilead. S. Biktarvy® (bictegravir, emtricitabine, and tenofovir alafenamide): US prescribing information; 2018. Available from: https://www.accessdata.fda.gov. Accessed 20 May, 2021.
   Google Scholar
• Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347–e356. doi:10.1016/S2352-3018(18)30091-229925490
   PubMed Web of Science ®Google Scholar
• Tsiang M, Jones GS, Goldsmith J, et al. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother. 2016;60(12):7086–7097. doi:10.1128/AAC.01474-1627645238
   PubMed Web of Science ®Google Scholar
• Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19(3):253–264. doi:10.1016/S1473-3099(19)30036-230732940
   PubMed Web of Science ®Google Scholar
• Paton N Nucleosides and darunavir/dolutegravir in Africa (NADIA) trial: 48 wks primary outcome. Oral abstract 94 at: Conference of Retroviruses and Opportunistic Infections.6–10 March 2021. 2021.
   Google Scholar
• Oliveira M, Ibanescu R-I, Anstett K, et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018;15(1):56. doi:10.1186/s12977-018-0440-330119633
   PubMed Web of Science ®Google Scholar
• Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus Abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357–e365. doi:10.1016/S2352-3018(18)30092-429925489
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020;71(6):1379–1389. doi:10.1093/cid/ciz99931606734
   PubMed Web of Science ®Google Scholar
• Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV. Clin Infect Dis. 2020;73:e485.
   Web of Science ®Google Scholar